Clinical Trial Update: A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical study evaluating HLX10 with albumin-bound paclitaxel in advanced cervical cancer after progression or intolerance to first-line chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• HLX10

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Cervical Cancer | Phase 2 | Status: UNKNOWN